Sector consensus Charles River Laboratories International, Inc.
Stocks
CRL
US1598641074
Biotechnology & Medical Research
|
Market Closed -
NYSE
16:00:03 2026-09-01 EDT
|
5-day change | 1st Jan Change | ||
| 282.34 USD | -2.05% |
|
-5.14% | +41.54% |
| 08-20 | Charles River Laboratories International Insider Sold Shares Worth $599,711, According to a Recent SEC Filing | MT |
| 08-20 | Charles River, Medigen Partner on Multivalent Enterovirus Vaccine | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 281 | -2.51% | 14 | ||||||
| 681.13 | +18.13% | 23 | ||||||
| 248.77 | +21.02% | 21 | ||||||
| 275.17 | +5.35% | 18 | ||||||
| 432.16 | +20.18% | 28 | ||||||
| 266,031.64 | +40.83% | 23 | ||||||
| 581.83 | -2.05% | 12 | ||||||
| 270.6 | +19.48% | 20 | ||||||
| 72.53 | -0.02% | 14 | ||||||
| 185.56 | +12.47% | 16 | ||||||
| 63.36 | +0.49% | 14 | ||||||
| 70.73 | -2.19% | 11 | ||||||
| 49.79 | +14.99% | 11 | ||||||
| 138.97 | +42.46% | 6 | ||||||
| 134.85 | -0.17% | 11 | ||||||
| 88 | +45.79% | 22 | ||||||
| 134.09 | +12.86% | 22 | ||||||
| 3.83 | -11.38% | 7 | ||||||
| 638.68 | +82.32% | 19 | ||||||
| 172.85 | +16.99% | 13 | ||||||
| Average | 13,527.78 | +16.75% | 16 | ||||||
| Weighted average by Cap. | 22,938.8 | +17.23% | 19 |
Select your edition
All financial news and data tailored to specific country editions
